Jubilant Pharmova Q4 Profit Slips 21% to Rs 119 Cr Despite Revenue Growth
New Delhi: Jubilant Pharmova reported a 21 per cent decline in consolidated net profit to Rs 119.3 crore in the March quarter impacted by exceptional items outgo.
The company had posted a consolidated net profit of Rs 151.3 crore in the corresponding period of the previous fiscal year, Jubilant Pharmova Ltd said in a regulatory filing.
Consolidated total revenue from operations during the quarter stood at Rs 2,290 crore as compared to Rs 1,928.8 crore in the year-ago period, it added.
Total expenses during the quarter under review were higher at Rs 2,124 crore from Rs 1,731.3 crore in the corresponding period a year ago, the company said.
The company incurred exceptional items outgo of Rs 13.7 crore in the quarter.
The board has recommended a final dividend of Rs 5 per equity share of face value of Re 1 each for the financial year ended March 31, 2026, it said.
For FY26, consolidated profit was down at Rs 397.5 crore from Rs 836.3 crore in FY25. Consolidated total revenue from operations in FY26 stood at Rs 8,279.6 crore as compared to Rs 7,234.5 crore in FY25, the company said.
They said the company anticipates EBITDA margins to strengthen from H2 FY27 onwards post- stabilisation of production in Montreal, effectively offsetting higher depreciation costs and driving net profit growth.
"Revenue growth is particularly driven by incremental revenue generation from the new and third line in CDMO (contract development and manufacturing organisation) sterile injectable business," Jubilant Pharmova Chairman Shyam S Bhartia and Co-Chairman & Non-Executive Director Hari S Bhartia said in a joint statement.
